ALLK Quote, Financials, Valuation and Earnings

Biogen has a net margin of -- compared to Allakos's net margin of 10.87%. Allakos's return on equity of -- beat Biogen's return on equity of 10.33%.

Allakos has a consensus price target of $0.37, signalling upside risk potential of 59.35%. On the other hand Biogen has an analysts' consensus of $200.12 which suggests that it could grow by 44.62%. Given that Allakos has higher upside potential than Biogen, analysts believe Allakos is more attractive than Biogen.

Allakos has a beta of 0.719, which suggesting that the stock is 28.106% less volatile than S&P 500. In comparison Biogen has a beta of 0.012, suggesting its less volatile than the S&P 500 by 98.773%.

Allakos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allakos pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

Allakos quarterly revenues are --, which are smaller than Biogen quarterly revenues of $2.5B. Allakos's net income of $376K is lower than Biogen's net income of $266.7M. Notably, Allakos's price-to-earnings ratio is -- while Biogen's PE ratio is 12.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allakos is -- versus 2.09x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Allakos's net margin of -49.65%. Allakos's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Allakos has a consensus price target of $0.37, signalling upside risk potential of 59.35%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 39.8%. Given that Allakos has higher upside potential than NovaBay Pharmaceuticals, analysts believe Allakos is more attractive than NovaBay Pharmaceuticals.

Allakos has a beta of 0.719, which suggesting that the stock is 28.106% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.363%.

Allakos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allakos pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Allakos quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Allakos's net income of $376K is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Allakos's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allakos is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Sage Therapeutics has a net margin of -- compared to Allakos's net margin of -747.33%. Allakos's return on equity of -- beat Sage Therapeutics's return on equity of -63.59%.

Allakos has a consensus price target of $0.37, signalling upside risk potential of 59.35%. On the other hand Sage Therapeutics has an analysts' consensus of $8.05 which suggests that it could fall by -2.83%. Given that Allakos has higher upside potential than Sage Therapeutics, analysts believe Allakos is more attractive than Sage Therapeutics.

Allakos has a beta of 0.719, which suggesting that the stock is 28.106% less volatile than S&P 500. In comparison Sage Therapeutics has a beta of 0.817, suggesting its less volatile than the S&P 500 by 18.337%.

Allakos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sage Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allakos pays -- of its earnings as a dividend. Sage Therapeutics pays out -- of its earnings as a dividend.

Allakos quarterly revenues are --, which are smaller than Sage Therapeutics quarterly revenues of $12.8M. Allakos's net income of $376K is higher than Sage Therapeutics's net income of -$95.8M. Notably, Allakos's price-to-earnings ratio is -- while Sage Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allakos is -- versus 12.20x for Sage Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals has a net margin of -- compared to Allakos's net margin of -9.24%. Allakos's return on equity of -- beat Vanda Pharmaceuticals's return on equity of -3.49%.

Allakos has a consensus price target of $0.37, signalling upside risk potential of 59.35%. On the other hand Vanda Pharmaceuticals has an analysts' consensus of $12.67 which suggests that it could grow by 170.08%. Given that Vanda Pharmaceuticals has higher upside potential than Allakos, analysts believe Vanda Pharmaceuticals is more attractive than Allakos.

Allakos has a beta of 0.719, which suggesting that the stock is 28.106% less volatile than S&P 500. In comparison Vanda Pharmaceuticals has a beta of 0.689, suggesting its less volatile than the S&P 500 by 31.079%.

Allakos has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allakos pays -- of its earnings as a dividend. Vanda Pharmaceuticals pays out -- of its earnings as a dividend.

Allakos quarterly revenues are --, which are smaller than Vanda Pharmaceuticals quarterly revenues of $53.2M. Allakos's net income of $376K is higher than Vanda Pharmaceuticals's net income of -$4.9M. Notably, Allakos's price-to-earnings ratio is -- while Vanda Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allakos is -- versus 1.37x for Vanda Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.